Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 6, 1998, Pages 464-468

  Blaney, Susan M ^a   Takimoto, Chris ^b   Murry, Daryl J ^a   Kuttesch, Nancy ^a   McCully, Cynthia ^b   Cole, Diane E ^b   Godwin, Karen ^b   Balis, Frank M ^b  

^a TEXAS CHILDREN S CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

9 Aminocamptothecin; CSF penetration; Irinotecan; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DRUG METABOLITE; IRINOTECAN; LACTONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; DRUG PENETRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RHESUS MONKEY; STEADY STATE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; MACACA MULATTA; MALE; NAUSEA; VOMITING;

EID: 0031887882     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050768     Document Type: Article

References (22)

1. Baker S, Heideman R, Crom W, Kuttesch J, Gajjar A, Stewart C (1996) Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 37: 195 202
2. Blaney S, Cole D, Balis F, Godwin K, McCully C, Poplack D (1992) Plasma and CSF pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53: 725-727
3. Burke T, Munshi C, Mi Z, Jiang Y (1995) The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 84: 518-519
4. Gihaldi M, Perrier D (1982) Estimation of areas. In: Swarbick J (ed) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, pp 445-449
5. Gupla E, Lesting T, Mick R, Ramirez J, Yokes E, Ratain M (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54: 3723-3725
6. Hertzberg R, Holden K, Secht S, Mattern M, Raucette L, Johnson R (1987) Characterization of structural features of camptothecin essential for topoisomerase I interaction and for induction of protein-linked DNA breaks in cells. Proc Am Assoc Cancer Res 28: 7
7. Houghton P, Cheshire P, Myers L, Houghton J (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxy camptothecin (topotecan) against xenografts derived from adult and childhood tumors. Ann Oncol 3 [Suppl 1]: A104
8. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu L, Saijo N (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50: 5919-5924
9. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K (1991) Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192-198
10. Knott G (1979) MLAB: a mathematical modeling tool. Comput Programs Biomed 10: 271-280
11. Liu L (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375
12. McCully C, Balis F, Bacher J, Phillips J, Poplack D (1990) A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40: 520-525
13. National Research Council (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington D.C.
14. Perrier D, Mayersohn M (1982) Noncompartmental determination of steady state volume of distribution for any mode of administration. J Pharm Sci 71: 372-373
15. Physician (1997) Physician's Desk Reference. Medical Economics Company, Inc., Montvale, NJ. Physician's Desk Reference 51: 2060
16. Rivory L, Robert J (1995) Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36: 176-179
17. Rivory L, Chatelut E, Canal P, Mathieu-Boue A, Robert J (1994) Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 54: 6330-6333
18. Rivory L, Bowles M, Robert J, Pond S (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52: 1103-1111
19. Sung C, Blaney S, Cole D, Balis F, Dedrick R (1994) A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 54: 5118-5112
20. Takimoto C, Klecker R, Dahut W, Yee L, Strong J, Allegra C, Grem J (1994) Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr 655: 97-104
21. Takimoto C, Dahut W, Marino M, Nakashima H, Liang M, Harold N, Lieberman R, Arbuck S, Band R, Chen A, Hamilton J, Cantilena L, Allegra C, Grem J (1997) Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 15: 1492-1501
22. Zamboni W, Crom W, Houghton P, Thompson J, Stewart C (1996) Plasma protein binding of SN-38: the active metabolite or irinotecan (abstract). Pharmacotherapy 16: 500